MTNB — Matinas BioPharma Holdings Share News
0.000.00%
Last trade - 00:00Brief: Matinas Biopharma To Discuss 2022 Financial Results And Provide Business Update On March 15
Brief: Matinas Biopharma Provides Business Update And 2023 Strategic Outlook
Brief: Matinas BioPharma To Provide Corporate Update, 2023 Business Outlook
Matinas BioPharma rises on tie-up for drug delivery technology
Brief: Matinas Biopharma Announces Collaboration With National Resilience To Explore And Evaluate Novel LNC Platform Delivery Technology For Certain Nucleic Acids
Brief: Matinas Biopharma Reports Q3 2022 Financial Results
Brief: Matinas Biopharma Holdings Reports Positive Interim Data From The Phase 2 Enact Trial Of Mat2203
Brief: Matinas Biopharma Announces Positive Interim Data From The Phase 2 Enact Trial Of Mat2203
Brief: Matinas Biopharma Announces Infectious Diseases Society Of America (Idsa) Has Selected The Enact Phase 2 Trial Abstract Of Mat2203 As Its Outstanding Abstract And Idsa Awardee For Idweek 2022
Brief: Matinas Biopharma Announces Chairman Succession Plan
Brief: Matinas Biopharma reports Q2 results
Brief: Matinas Biopharma - remains in discussions with Biontech for option to license lnc platform for MRNA on an exclusive basis
Brief: Matinas BioPharma Announces Positive Opinion By The European Medicines Agency On Orphan Drug Designation For MAT2203 For The Treatment Of Cryptococcosis
Brief: Matinas Biopharma Reports First Quarter 2022 Financial Results And Operational Highlights
Brief: Matinas Biopharma Holdings Says Under Agreement With Biontech, Co Will Receive Exclusivity Fee Of $2.75 Mln
Brief: BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration
Brief: Matinas Biopharma Provides Business Update And 2022 Strategic Outlook
Matinas up on safety panel nod for fungal infection trial progression
Brief: Matinas Biopharma Announces Unanimous DSMB Approval To Progress Into Fourth And Final Cohort Of Patients In The Enact Trial Of MAT2203